On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to-severe plaque psoriasis (PSO).

In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% achieved complete skin clearance (PASI100+) at five years.

Among patients with PSO only at baseline, at risk of progression to psoriatic arthritis, 68.7–71.6% achieved complete skin clearance at three years, generally consistent with the overall treated group, who achieved 72%.

In this subgroup over the five years, bimekizumab was generally well tolerated with no unexpected safety findings.

Also Read: FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

Concurrently, UCB released two-year data from the BE HEARD trials for Bimzelx in moderate to severe hidradenitis suppurativa (HS).

In 425 HS patients with ≥1 draining tunnels (DTs) at baseline, 55.7% (195/350) had no DTs at two years of treatment. 41.1% had no DTs at two years.

DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently leading to scarring.

Among patients with one or more DTs at baseline, the proportion who had 1–2, 3–5, or >5 DTs at two years were 26.6%, 11.1%, and 6.6%, respectively.

At two years of bimekizumab treatment, 63.6% (279/439) of patients reported no or mild skin pain, compared to 10.0% (55/551) at baseline.

Price Action: UCBJY stock is down 0.87% at $102.41 at the last check Friday.

Read Next:

• Eli Lilly's Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients

Image via Shutterstock